| Name | Title | Contact Details |
|---|---|---|
Jonathan Jagoda |
Senior Vice President of Legislative Affairs | Profile |
Abigail Kaericher |
Vice President of Legislation and Associate General Counsel | Profile |
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
A.R.E.B.A. Casriel is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sebra (DBA) is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
We are one of the nation`s first health departments and trace our roots back to 1799, when Paul Revere was named Boston`s first health officer. Back then, the board of health was formed to fight a potential outbreak of cholera. Taking innovative strides to save lives, health officials posted signs on lampposts, held meetings and led an early-day public information campaign to reduce deaths due to cholera, a highly preventable disease. Two hundred years later, that tradition of prevention continues through the Boston Public Health Commission. While we are the country`s oldest health department, we pride ourselves on having some of the most innovative services for our residents. Described as "the most activist arm of city government," by the Boston Globe, the Commission has a vigorous commitment to the health of Boston.
McBride Orthopedic Hospital opened in 2005 as a full-service orthopedic hospital. McBride has grown to include a board-certified physician staff of 28, practicing at five metro locations and several outreach clinics in rural communities. The physicians continue their close involvement with athletes of all ages, serving as team physicians for many of the local professional, collegiate, and high school athletes.